Ligand id: 8445

Name: beloranib

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 6
Hydrogen bond donors 0
Rotatable bonds 12
Topological polar surface area 73.06
Molecular weight 499.29
XLogP 3.91
No. Lipinski's rules broken 1

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Beloranib is being evaluated in Phase III clinical trial as a potential treatment for obese patients with Prader-Willi syndrome. A Phase II study in obese patients with type 2 diabetes mellitus is also underway.
Mechanism Of Action and Pharmacodynamic Effects
Beloranib is a prototype methionine aminopeptidase 2 (MetAP2) inhibitor. MetAP2 inhibitors were originally developed as anti-cancer agents [1,4-6] but are now being exploited for their ability to induce significant and sustained weight reduction, without serious side effects [2-3]. Beloranib both decreases the drive to eat and increases the use of stored fat as an energy source to achieve the drug's clinical effects.